SU2C phase Ib study of the PI3Kα inhibitor BYL719 with letrozole in ER+/HER2– metastatic breast cancer (MBC).
Ingrid A. Mayer
Research Funding - Novartis
Vandana Gupta Abramson
No relevant relationships to disclose
Justin M. Balko
No relevant relationships to disclose
Melinda Sanders
No relevant relationships to disclose
Dejan Juric
Research Funding - Novartis
Yisheng Li
No relevant relationships to disclose
Lewis Cantley
No relevant relationships to disclose
Eric P. Winer
Consultant or Advisory Role - Novartis
Carlos L. Arteaga
Consultant or Advisory Role - Novartis